DLL3: an emerging target in small cell lung cancer

Table 2 Clinical trials of DLL3-targeted therapies in SCLC that have been completed

Treatment	Setting	Primary objective	Phase	N	ID	Results	Ref.
Rovalpituzumab tesirine	SCLC, LCNEC	Safety	1/2	82 (74 SCLC)	NCT01901653	ORR, 18% (11/60)	[36]
Rovalpituzumab tesirine	SCLC, 3rd line, and beyond	ORR, OS	2	339	NCT02674568	ORR, 12.4% (9.1, 16.4); median OS, 5.6 months (4.9, 6.1)	[37]

LCNEC large cell neuroendocrine cancer, ORR overall response rate, OS overall survival, SCLC small cell lung cancer

ISSN: 1756-8722